Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J BUON ; 18(2): 413-9, 2013.
Article in English | MEDLINE | ID: mdl-23818354

ABSTRACT

PURPOSE: Metastatic renal cell carcinoma (mRCC) bears a poor prognosis. We investigated the prognostic significance of some hematologic parameters of patients with mRCC. METHODS: We retrospectively reviewed the records of 53 patients with mRCC . The mean follow up time was 34 months (range 5-142).We assessed the prognostic value of hematologic parameters (leukocytes ,neutrophils, lymphocytes, platelets, neutrophil to lymphocyte ratio/NLR, platelet to lymphocyte ratio/PLR), and other clinical parameters with univariate and multivariate analysis. RESULTS: Memorial Sloan-Kettering Cancer Center (MSKCC) risk group , lung metastases, sunitinib treatment, lymphocyte count, NLR, and anemia significantly correlated with median overall survival (OS) on univariate analysis. The median OS in patients with a NLR < 3.4 was 32.2 months , significantly higher than the 13.9 months in patients with a ratio ≥ 3.4 (p = 0.006). Multivariate analysis revealed that MSKCC risk group and the NLR were independent predictors of OS. CONCLUSION: Hematologic parameters may be associated with OS in mRCC. However, further studies are needed to establish their routine use.


Subject(s)
Blood Platelets , Carcinoma, Renal Cell/blood , Carcinoma, Renal Cell/secondary , Kidney Neoplasms/blood , Kidney Neoplasms/pathology , Lymphocytes , Neutrophils , Adult , Aged , Antineoplastic Agents/therapeutic use , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/therapy , Female , Humans , Indoles/therapeutic use , Kaplan-Meier Estimate , Kidney Neoplasms/mortality , Kidney Neoplasms/therapy , Lymphocyte Count , Male , Middle Aged , Multivariate Analysis , Platelet Count , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Protein Kinase Inhibitors/therapeutic use , Pyrroles/therapeutic use , Retrospective Studies , Risk Factors , Sunitinib , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...